RE:Conf call agenda You've jogged my memory a bit with your questions.
There's a mgmt lockup preventing mgmt to buy Ausa shares until after they release their financials
Ausa said they don't seen value in a share buyback but will consider it if it creates the most value for their cash
Merger fell through after doing an audit on 2 years of their financials
They keep emphasizing that Ausa and ACB are separate companies, decisions are independant and no one sits on each other's boards
They have no plans to issue shares for acquisitions
Will provide update on 26th in regards to their thc assets
They are focusing on cocoon atm.
Smokininvesta wrote:
Here is what I would like to see:
- folium summary - deal is dead, provide some reasoning, summary of costs of deal. With dropping CBD prices and FDA/ GW Pharma IP protectionist moves as an AUSA shareholder I am THRILLED the deal is dead;
- go forward plan - what is it? Cocoon fintech rollout, upcoming M&A, value prop for go forward plan? Provide some of the rationale around previous seeds planted/ $$ spent with coccoon/ rapid cash to appease Chipper reasonable and thoughtful questions on previous post;
- valuation/ guidance of sorts on go forward plan - what is revenue model going to look like. What are comparable pubcos to determine trading multiple? Multiple likely WAY higher
- capital raising ability - with new go forward plan how will Ausa raise $$$? Will it be dilutive to current shareholders? Will dilutive financing even be needed?
- existing suite of assets - do THC assets still need to be sold? Any buyers or deals underway?
- C suite and BOD - any additions and/ or subtractions?
- share buy backs and insider buying. Are insiders locked up from buying at these levels? If not, will we see a bunch of insider buying at these low levels once that news becomes public
- any ties to ACB still? How does AcB warrant work now?
I think these are reasonable questions that hopefully are basis for very productive and accretive conversation for shareholders this upcoming week